Impax Laboratories (IPXL) Receives Analyst Rating

Impax Laboratories (IPXL) : 3 brokerage houses believe that Impax Laboratories (IPXL) is a Strong Buy at current levels. 6 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Impax Laboratories (IPXL). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 9 Wall Street Analysts endorse the stock as a Buy with a rating of 2.33.

Impax Laboratories (IPXL) : Average target price received by Impax Laboratories (IPXL) is $28 with an expected standard deviation of $3.16. The most aggressive target on the stock is $32, whereas the most downbeat target is $24. 8 financial analysts are currently covering the stock.


Also, Equity Analysts at the Brokerage Firm, Northland Securities, upgrades their rating on the shares of Impax Laboratories (NASDAQ:IPXL). Northland Securities has a Outperform rating on the shares. Previously, the analysts had a Market Perform rating on the shares. The rating by the firm was issued on August 15, 2016.

Impax Laboratories (NASDAQ:IPXL): After opening at $25.33, the stock dipped to an intraday low of $25.04 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $25.9 and the buying power remained strong till the end. The stock closed at $25.88 for the day, a gain of 1.93% for the day session. The total traded volume was 708,410. The stocks close on the previous trading day was $25.39.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.